Clinical Trial Update: Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SLN360 in participants with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease. The trial is completed and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Atherosclerotic Cardiovascular Disease

Drugs mentioned

• SLN360

Snippet

Sponsor: Silence Therapeutics plc | Conditions: Cardiovascular Diseases, Atherosclerosis | Phase 2 | Status: COMPLETED | Results posted: 2025-07-01